In glaucoma, the nerve to the eye (the “optic nerve”) becomes progressively damaged. This leads to loss of peripheral vision, and in advanced cases, blindness.
Historically, damage to the optic nerve in glaucoma has been thought to be the result of high eye pressure. The main treatment for glaucoma has been to use eye drops or surgery to lower the eye pressure to try to stop damage to the optic nerve from progressing.
In most people with glaucoma, however, optic nerve damage and visual loss continue despite lowering of the eye pressure. This means there is something wrong besides high eye pressure. Until now, this other “something wrong” has been a mystery.
Because lowering eye pressure is not enough, scientists have searched for many years to find treatments that will protect the optic nerve from damage. This is called “neuroprotection”.
RPT is the first and only neuroprotective treatment for glaucoma. RPT is the first treatment to improve the health and function of the optic nerve, vision, and visual fields in glaucoma without lowering eye pressure. The improvements in optic nerve function and vision produced by RPT are very significant. Because these improvements are achieved by treating the retina, the results of RPT suggest that glaucoma may actually be a retinal problem, rather than an eye pressure problem. This represents a major breakthrough in both the treatment and understanding of glaucoma. By treating regularly to maintain the neuroprotective effects of RPT, RPT can safely reduce your risk of vision loss if you have glaucoma, even if your eye pressures are well controlled.
Vision loss progression in glaucoma
Normal optic nerve
Optic nerve damaged by glaucoma